Immune cells injected into brain show promise against deadly cancer

NCT ID NCT03383978

Recruiting now Disease control Sponsor: Johann Wolfgang Goethe University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment for people with a recurring type of brain cancer called glioblastoma. The treatment uses specially designed immune cells (NK-92/5.28.z) that are injected directly into the brain to attack cancer cells. The main goals are to check safety, find the best dose, and see if the treatment can shrink tumors or slow the disease. Some participants will also receive an additional immunotherapy drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Johann W. Goethe University Hospital, Department of Neurosurgery
RECRUITING

Frankfurt, 60590, Germany
Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology
RECRUITING

Frankfurt, 60590, Germany
Neurochirurgische Klinik, Universitätsklinikum Heidelberg
RECRUITING

Heidelberg, Baden-Wurttemberg, 69120, Germany
Neurochirurgische Klinik, Universitätsmedizin Mainz
RECRUITING

Mainz, Rhineland-Palatinate, 55131, Germany
Neurochirurgische Klinik, Universitätsmedizin Mannheim
RECRUITING

Mannheim, Baden-Wurttemberg, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.